Skip to main navigation
Compass Therapeutics
  • Home
  • About
  • Platform
  • Pipeline
  • Clinical Trials
  • Join Us
  • Investors
  • Contact

News Releases

Investor Menu
  • Home
  • News & Events
    • News Releases
    • Events
    • Presentations
    • In the News
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Leadership Team
    • Board of Directors
    • Committee Composition
  • Financial & FIlings
    • SEC Filings
    • Annual Meeting
    • Annual Reports
    • Quarterly Results
Jan 19, 2023
Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023
Additional Formats
PDF Version
Jan 06, 2023
Compass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer
Additional Formats
PDF Version

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
Displaying 11 - 12 of 12

IR Contact

IR@compasstherapeutics.com

Media Contact

Anna Gifford, Communications Manager

Anna.Gifford@compasstherapeutics.com

Email Alerts

  • © 2023 Compass Therapeutics, Inc.
  • Terms & Conditions
  • Privacy Policy
  • Home
  • About
  • Platform
  • Pipeline
  • Clinical Trials
  • Join Us
  • Investors
  • Contact